Behnaz Aminossadati

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

Anja Rinke, Hans‐Helge Müller, Carmen Schade‐Brittinger et al. · Journal of Clinical Oncology · 2009 · 2.5K citations

Medicine, Oncology, Pharmacotherapy +17

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

Jürgen Behr, Antje Prasse, Michael Kreuter et al. · The Lancet Respiratory Medicine · 2021 · 516 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +9

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival

Anja Rinke, Michael Wittenberg, Carmen Schade‐Brittinger et al. · Neuroendocrinology · 2016 · 384 citations

Medicine, Oncology, Pharmacology +17

Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group

R. Arnold, Carmen Schade‐Brittinger, Anja Rinke et al. · Journal of Clinical Oncology · 2009 · 197 citations

Medicine, Oncology, Pharmacotherapy +17

Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial

Eugénie Lhommée, Lars Wojtecki, Virginie Czernecki et al. · The Lancet Neurology · 2018 · 169 citations · Full text

Medicine, Neurology, Neuroscience +17